Peregrine Pharmaceuticals Inc. (PPHM) - NASDAQ
  • Wed, Mar. 9, 9:14 AM
    • Peregrine Pharmaceuticals (PPHM) FQ3 results: Revenues: $6.7M (+17.5%); R&D Expense: $15.2M (+34.5%); SG&A: $4.5M (+4.7%); Operating Loss: ($16.9M) (-30.0%); Net Loss: ($18.2M) (-30.0%); Loss Per Share: ($0.08) (unch); Quick Assets: $67.5M (-0.7%).
    • No guidance given.
    | Wed, Mar. 9, 9:14 AM
  • Wed, Mar. 9, 8:03 AM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ3 EPS of -$0.08 misses by $0.01.
    • Revenue of $6.71M (+18.1% Y/Y) misses by $1.25M.
    • Press Release
    | Wed, Mar. 9, 8:03 AM
  • Tue, Mar. 8, 5:30 PM
    | Tue, Mar. 8, 5:30 PM | 1 Comment
  • Fri, Feb. 26, 3:58 PM
    • Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird
    • Insulet (PODD +8.5%) upgraded to Buy from Hold with a $40 (25% upside) price target by Benchmark.
    • DENTSPLY (XRAY -0.1%) upgraded to Neutral from Sell by UBS. Price target raised to $60 (1% downside risk) from $50.
    • PTC Therapeutics (PTCT -29.4%) upgraded Hold from Underperform by Jefferies. Price target lowered to $12 (22% upside) from $18.
    • AbbVie (ABBV -0.3%) upgraded to Buy from Neutral by Citigroup. Price target raised to $65 (16% upside) from $56.
    • Wellcare Health Plans (WCG +0.7%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $114 (24% upside) from $80.
    • Keryx Biopharmaceuticals (KERX +8.7%) downgraded to Neutral from Overweight by JP Morgan.
    • Peregrine Pharmaceuticals (PPHM -62.1%) downgraded to Neutral from Buy with a $0.50 (25% upside) price target by Roth Capital.
    • EXACT Sciences (EXAS -1.8%) downgraded to Neutral from Buy by Roth Capital and Equal Weight from Overweight by Stephens & Co.
    • Radius Health (RDUS -2.8%) downgraded to Hold from Buy with a $37 (23% upside) price target by Jefferies.
    • PTC Therapeutics (PTCT -29.4%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $13 (56% upside) from $90.
    • Orexigen (OREX -31.9%) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $2 (104% upside) from $4.50.
    • Express Scripts (ESRX +2.4%) downgraded to Sell from Hold by Deutsche Bank. Price target lowered to $61(15% downside risk) from $93.
    • Perrigo (PRGO) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $124 (4% downside risk) from $160.
    • Chimerix (CMRX -6.6%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $9 (91% upside) from $13.
    | Fri, Feb. 26, 3:58 PM | 8 Comments
  • Fri, Feb. 26, 12:45 PM
    | Fri, Feb. 26, 12:45 PM | 4 Comments
  • Fri, Feb. 26, 11:52 AM
    • Nano cap Peregrine Pharmaceuticals (PPHM -62.6%) craters on more than 10x normal volume in response to its announcement that lead product candidate, Fast Track-tagged bavituximab, failed a Phase 3 clinical trial, SUNRISE, in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
    • The company terminated the trial based on the recommendation of the Independent Data Monitoring Committee following a pre-planned interim analysis after 33% of the targeted events (patient deaths) occurred. The results did not show a sufficient improvement in overall survival (OS) in the bavituximab plus docetaxel cohort compared to the docetaxel-only group. The problem was not bavituximab, which performed as expected, but docetaxel, which significantly outperformed expectations as measured by OS.
    • Despite the setback, the company remains committed to advancing bavituximab combination studies such as the one with AstraZeneca's(AZN -0.9%) durvalumab.
    • Bavituximab is a monoclonal antibody that binds to a cell membrane component called phosphatidylserine, a highly immunosuppressive molecule that is usually resides inside the membrane of healthy cells. In tumor blood vessels, however, it becomes exposed on the outside of cells, thereby creating a target for anticancer therapies.
    • Previously: Peregrine Pharma, AstraZeneca to collaborate on immuno-oncology trial (Aug. 24, 2015)
    | Fri, Feb. 26, 11:52 AM | 8 Comments
  • Fri, Feb. 26, 9:17 AM
    | Fri, Feb. 26, 9:17 AM | 7 Comments
  • Dec. 11, 2015, 6:25 AM
    • Peregrine Pharmaceuticals (PPHM +1.7%) FQ2 results: Revenues: $9.5M (+50.8%); R&D Expense: $14.2M (+42.0%); SG&A: $4.4M (+2.3%); Operating Loss: ($13.8M) (-14.0%); Net Loss: ($13.2M) (-9.1%); Loss Per Share: ($0.07) (unch); Quick Assets: $72M (+5.9%).
    • FY2016 Guidance: Third-party contract manufacturing revenue: $35M - 40M from $30M - $35M.
    | Dec. 11, 2015, 6:25 AM | 1 Comment
  • Dec. 10, 2015, 4:08 PM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ2 EPS of -$0.07 beats by $0.02.
    • Revenue of $9.52M (+51.1% Y/Y) beats by $2.02M.
    | Dec. 10, 2015, 4:08 PM | 2 Comments
  • Dec. 9, 2015, 5:35 PM
  • Oct. 15, 2015, 9:13 AM
    | Oct. 15, 2015, 9:13 AM
  • Sep. 10, 2015, 6:51 AM
    • Peregrine Pharmaceuticals (PPHM -3.2%) FQ1 results: Revenues: $9.7M (+76.4%); COGS: $4.6M (+27.8%); R&D Expense: $13.9M (+36.3%); SG&A: $4.9M (+0.3%); Operating Loss: ($13.8M) (-4.5%); Net Loss: ($15.1M) (-6.3%); Loss Per Share: ($0.08) (unch); Quick Assets: $59M (-13.2%).
    • No guidance given.
    | Sep. 10, 2015, 6:51 AM
  • Sep. 9, 2015, 4:10 PM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM): FQ1 EPS of -$0.08 in-line.
    • Revenue of $9.67M (+75.8% Y/Y) beats by $2.64M.
    | Sep. 9, 2015, 4:10 PM
  • Sep. 7, 2015, 5:35 PM
    | Sep. 7, 2015, 5:35 PM | 6 Comments
  • Aug. 24, 2015, 8:47 AM
    • Peregrine Pharmaceuticals (NASDAQ:PPHM) and AstraZeneca (NYSE:AZN) announce plans for a cancer immunotherapy clinical trial collaboration to evaluate PPHM's investigational phosphatidylserine-signaling pathway inhibitor, bavituximab, in combination with AZN's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab.
    • The companies say they will collaborate on a non-exclusive basis, to evaluate the combination of bavituximab and durvalumab with chemotherapy as a potential treatment in various solid tumors.
    • PPHM +5.2%, AZN -1.2% premarket.
    | Aug. 24, 2015, 8:47 AM | 1 Comment
  • Jul. 15, 2015, 6:58 AM
    • Peregrine Pharmaceuticals (PPHM +2.3%) FQ4 results: Revenues: $9.3M (+43.1%); COGS: $4.8M (+26.3%); R&D Expense: $11.5M (+30.7%); SG&A: $5.2M (+18.2%); Operating Loss: ($12.2M) (-16.2%); Net Loss: ($12.1M) (-17.5%); Loss Per Share: ($0.07) (-16.7%).
    • FY2015 results: Revenues: $26.8M (+19.6%); COGS: $15.6M (+19.1%); R&D Expense: $43M (+55.2%); SG&A: $18.7M (+8.1%); Operating Loss: ($50.5M) (-41.5%); Net Loss: ($50.4M) (-42.4%); Loss Per Share: ($0.30) (-36.4%); Quick Assets: $68M (-12.3%).
    • No guidance given.
    | Jul. 15, 2015, 6:58 AM | 2 Comments
Company Description
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company engages in the provision of monoclonal antibody therapeutics. It carries its operation through peregrine and avid segments. The peregrine segment refers to research and development of monoclonal antibodies for the treatment and... More
Sector: Healthcare
Industry: Biotechnology
Country: United States